Ameriprise
VTGN icon

Ameriprise’s VistaGen Therapeutics VTGN Stock Holding History

Ameriprise’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-362
Closed -$1.35K – 4011
2023
Q1 		$1.35K Buy
+362
New +$1.9K ﹤0.01% 3931
2022
Q4 		– Sell
-726
Closed -$3K – 4056
2022
Q3 		$3K Buy
+726
New +$7.2K ﹤0.01% 3946

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's VTGN Position: Q2 2023 in Review

Ameriprise sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 362 shares — an estimated $1.35K sold.

Ameriprise first reported a position in VTGN in Q3 2022 and held it in 2 quarters. The position peaked at $3K in Q3 2022. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Ameriprise reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ameriprise sold 362 VistaGen Therapeutics shares in Q2 2023, an estimated $1.35K.
  • Ameriprise first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 2 quarters.
  • Ameriprise's VistaGen Therapeutics position peaked at $3K in Q3 2022.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.